Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,050 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cell Transfer Clear all

Conditions: Idiopathic CD4 Lymphopenia
Interventions: Belimumab; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Refractory Angina, Chronic Myocardial Ischemia
Interventions: CardiAMP Cell Therapy System, Sham Treatment; Device · Other
Lead sponsor: BioCardia, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Gainesville, Florida • Madison, Wisconsin

Conditions: Retinitis Pigmentosa
Interventions: DSP-3077 Retinal Sheet Cohort 1, DSP-3077 Retinal Sheet Cohort 2, DSP-3077 Retinal Sheet Cohort 3; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Boston, Massachusetts • Minneapolis, Minnesota

Conditions: Lysosomal Diseases, Gangliosidosis, GM1
Interventions: AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam; Biological · Procedure · Drug + 3 more
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 6 Months to 12 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Ocrelizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more

Conditions: HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Endocervical Adenocarcinoma, Cervical Cancer, Oropharynx Cancer, Anal Cancer, Vulvar Cancer, Penile Cancer, Vaginal Cancer
Interventions: E7 TCR-T cells, Aldesleukin; Biological · Drug
Lead sponsor: Christian Hinrichs; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: New Brunswick, New Jersey

Conditions: BK Virus Nephropathy, BK Virus Infection
Interventions: Posoleucel (formerly known as ALVR105) cells, Placebo (visually identical to Posoleucel); Biological
Lead sponsor: AlloVir; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 33
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 27 more

Conditions: Inclusion Body Myositis
Interventions: Sirolimus, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 45 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Kansas City, Kansas • Baltimore, Maryland

Conditions: Opioid Dependence
Interventions: Medsignals, smartphone app; Device
Lead sponsor: Care Team Solutions; Industry
Eligibility: 21 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: HER2-positive Breast Cancer, Advanced Breast Cancer
Interventions: Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Phoenix, Arizona • Miami, Florida • Boston, Massachusetts

Conditions: Renal Artery Stenosis, Ischemic Nephropathy, Renovascular Disease, Chronic Kidney Disease
Interventions: Mesenchymal stem cell, Mesenchymal stem cell delivery with stent placement; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, Minnesota • Jackson, Mississippi

Conditions: Melanoma, Metastatic Melanoma, Malignant Melanoma, Skin Cancer
Interventions: Allovectin-7®; Genetic
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 16
States / cities: Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 13 more

Conditions: Head and Neck Cancer
Interventions: Nivolumab, Ipilimumab, Standard of Care Surgery; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
Interventions: CAR T Cells; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2040
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Metastatic Melanoma
Interventions: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells, non-myeloablative conditioning chemotherapy; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty; Drug · Procedure
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 51
States / cities: Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions: Tetanus; Biological
Lead sponsor: Robert Krance; Other
Eligibility: 3 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Diabetic Foot, Venous Ulcer, Pressure Ulcer
Interventions: Adipose derived stem cells; Drug
Lead sponsor: Tower Outpatient Surgical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Spinal Fusion
Interventions: Bone Marrow Aspirate Concentrate (BMAC) + Allograft, Recombinant Human Bone Morphogenetic Protein-2 (BMP), Autograft; Device · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia
Interventions: Busulfan, Fludarabine, Clofarabine, Total Body Irradiation (TBI), Thymoglobulin, Stem Cell Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Decitabine, Cytarabine, Idarubicin; Drug · Radiation · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Cancer
Interventions: Rexin-G Dose 1, Rexin-G Dose 2, Rexin-G Dose 3, Rexin-G Dose 4; Genetic
Lead sponsor: Epeius Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: High-grade Glioma, WHO Grade Ⅳ Glioma
Interventions: Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103; Biological
Lead sponsor: Tcelltech Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Trauma Injury, Trauma Blunt, Vascular Trauma
Interventions: Packed Red Blood Cell Administration; Other
Lead sponsor: Arrowhead Regional Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Colton, California

Conditions: Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloproliferative Disorders
Interventions: ARA C, Cyclophosphamide, MESNA, Total Body Irradiation (TBI), Campath-1h, Stem Cell Infusion; Drug · Radiation · Biological + 1 more
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia

Phase III Trial of Sirolimus in IBM

Using mHealth to Aid Opioid Medication Adherence Pilot Study

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

Hypoxia and Inflammatory Injury in Human Renovascular Hypertension

Phase II Trial of Allovectin-7® for Metastatic Melanoma

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Study of Gene Modified Immune Cells in Patients With Advanced Melanoma

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR

Adipose Derived Regenerative Cellular Therapy of Chronic Wounds

BMAC & Allograft vs BMP-2

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

Extremity Trauma At a Level 1 Trauma Center

T-Reg Cell Kinetics, Stem Cell Transplant, REGALE